AIM Relative Valuation
AIM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AIM is overvalued; if below, it's undervalued.
Historical Valuation
AIM ImmunoTech Inc (AIM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.17. The fair price of AIM ImmunoTech Inc (AIM) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.47
Fair
-0.34
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
AIM ImmunoTech Inc. (AIM) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.33
EV/EBIT
AIM ImmunoTech Inc. (AIM) has a current EV/EBIT of -0.33. The 5-year average EV/EBIT is -0.52. The thresholds are as follows: Strongly Undervalued below -2.65, Undervalued between -2.65 and -1.58, Fairly Valued between 0.55 and -1.58, Overvalued between 0.55 and 1.61, and Strongly Overvalued above 1.61. The current Forward EV/EBIT of -0.33 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
AIM ImmunoTech Inc. (AIM) has a current PS of 0.00. The 5-year average PS is 237.79. The thresholds are as follows: Strongly Undervalued below -180.19, Undervalued between -180.19 and 28.80, Fairly Valued between 446.77 and 28.80, Overvalued between 446.77 and 655.76, and Strongly Overvalued above 655.76. The current Forward PS of 0.00 falls within the Undervalued range.
-0.36
P/OCF
AIM ImmunoTech Inc. (AIM) has a current P/OCF of -0.36. The 5-year average P/OCF is -3.51. The thresholds are as follows: Strongly Undervalued below -10.30, Undervalued between -10.30 and -6.91, Fairly Valued between -0.11 and -6.91, Overvalued between -0.11 and 3.28, and Strongly Overvalued above 3.28. The current Forward P/OCF of -0.36 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
AIM ImmunoTech Inc. (AIM) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.53. The thresholds are as follows: Strongly Undervalued below -3.73, Undervalued between -3.73 and -2.13, Fairly Valued between 1.06 and -2.13, Overvalued between 1.06 and 2.66, and Strongly Overvalued above 2.66. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
AIM ImmunoTech Inc (AIM) has a current Price-to-Book (P/B) ratio of -0.64. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately -140.65% higher. Relative to its 5-year average P/B ratio of 1.37, the current P/B ratio is about -146.35% higher. AIM ImmunoTech Inc (AIM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -121.42%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -81.52% , the current FCF yield is about -100.00% lower.
-0.67
P/B
Median3y
1.57
Median5y
1.37
-323.61
FCF Yield
Median3y
-121.42
Median5y
-81.52
Competitors Valuation Multiple
The average P/S ratio for AIM's competitors is 0.00, providing a benchmark for relative valuation. AIM ImmunoTech Inc Corp (AIM) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -25.71%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AIM increased by 642.42% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.01 to -0.10.
The secondary factor is the Margin Expansion, contributed 19.48%to the performance.
Overall, the performance of AIM in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is AIM ImmunoTech Inc (AIM) currently overvalued or undervalued?
What is AIM ImmunoTech Inc (AIM) fair value?
How does AIM's valuation metrics compare to the industry average?
What is the current P/B ratio for AIM ImmunoTech Inc (AIM) as of Dec 05 2025?
What is the current FCF Yield for AIM ImmunoTech Inc (AIM) as of Dec 05 2025?
What is the current Forward P/E ratio for AIM ImmunoTech Inc (AIM) as of Dec 05 2025?